UPSTREAM BIO INC
UPBNASDAQ🏆 #3726 by market capUS Equity
$3.26▲ $0.28 (+9.40%)
After hours · at closeTrack UPB
Get earnings, price moves & breaking news on Telegram
24h▲ 9.4%
7d▲ 9.4%
14d▼ 2.8%
30d▼ 37.3%
ytd▼ 88.0%
1y▼ 86.5%
🏦Market Cap
$179M
Small Cap
📈Revenue Growth (YoY)
20.4%
Healthy
📊Gross Margin
98.5%
High
💵FCF Margin
-4317.4%
Thin
⚖️P/S Ratio
51.7x
Expensive
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $2.98 – $3.32
- 52-Week Range
- $2.68 – $33.68
- Volume (shares)
- 87,121
- Avg Volume (shares)
- —
- Shares Outstanding
- 54.8M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- $773,000
- P/E Ratio
- -1.0
- P/S Ratio
- 51.7x
- EPS (TTM)
- $-2.87
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +5.6%
UPSTREAM BIO INC
UPBFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$3M▲ +20.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$160M▲ +106.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$133M▲ +123.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
54.2M▲ +5.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$100M▼ −$224M YoY
StockOtter · stockotter.spaceAbout UPSTREAM BIO INC
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.
Latest News & Updates
News unavailable.